GENETIC SUSCEPTIBILITY TO LIPID-LOWERING DRUG-INDUCED MYOPATHIES

对降脂药物引起的肌病的遗传易感性

• 批准号: 8174438
• 负责人: MICHAEL H. WEISMAN
• 金额: $ 1.66万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174438
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Gene Mutation; Genetic Predisposition to Disease; Grant; High Prevalence; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Individual; Institution; Lipids; Metabolic; Myopathy; Patients; Pharmaceutical Preparations; Recruitment Activity; Research; Research Personnel; Resources; Source; United States National Institutes of Health

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine if individuals who are treated with HMG-CoA reductase inhibitors and develop myopathy have a higher prevalence of genetic mutations causing metabolic muscle diseases. Two-hundred patients will be recruited into the study.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该研究的目的是确定接受HMG-CoA还原酶抑制剂治疗并发生肌病的个体是否具有导致代谢性肌肉疾病的基因突变的较高患病率。 本研究将招募200名患者。